23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › KURA ONCOLOGY INC. › 2023-2024

KURA ONCOLOGY INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and KURA ONCOLOGY INC.’s Form 8-K, filed June 7, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 183Asset managers, any item
  • 1,100Fund votes
  • June 5, 2024Meeting date

Results at a glance

Meeting of June 5, 2024: 5 items on KURA ONCOLOGY INC.’s Form 8-K, filed June 7, 2024: 3 approved · 2 passed (calculated).

Dissent

Notable dissent: 2 directors (11.5%, 10.9% against); 1 other board item (18.3% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore KURA ONCOLOGY INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by KURA ONCOLOGY INC.

These tallies are KURA ONCOLOGY INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 7, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

KURA ONCOLOGY INC. — official shareholder meeting results, meeting held June 5, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Troy E. Wilson, Ph.D., J.D. 59,332,182---- 7,740,3822,690,089 88%Passed (calculated)—
Elect Director: Faheem Hasnain 59,745,514---- 7,327,0502,690,089 89%Passed (calculated)—
2. Ratification of the Selection of Independent Registered Public Accounting Firm 69,596,81156,740109,102 ---- 99.9%Approved—
3. Advisory Vote on Executive Compensation 61,538,6935,449,767111,285 --2,662,908 92%Approved—
4. Approval of our Amended 2014 Plan 53,621,81811,993,3941,484,533 --2,662,908 82%Approved—

Source: KURA ONCOLOGY INC., Form 8-K, filed with the SEC on June 7, 2024 — read the filing on EDGAR.

How asset managers voted at the KURA ONCOLOGY INC. 2023-2024 meeting

183 asset managers disclosed a vote on at least one KURA ONCOLOGY INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Faheem Hasnain

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%
FOR: 59,745,514WITHHELD: 7,327,050
Details: description as filed, official tally, votes by 58 asset managers

Description as filed by funds: Election of two Class I directors for three-year terms: Faheem Hasnain

KURA ONCOLOGY INC.’s own tally for this item (“Elect Director: Faheem Hasnain”): 59,745,514 for, 7,327,050 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 58 asset managers below reported 14,540,147 for, 1,928,217 withheld.

FOR
FOR: 14,540,147WITHHOLD: 1,928,217
Largest asset managers voting on “Election of two Class I directors for three-year terms: Faheem Hasnain” at KURA ONCOLOGY INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard3,968,5620 00For
BlackRock3,144,0960 00For
State Street2,554,0880 037,562For
Fidelity1,706,6930 00For
Dimensional00 0996,915Withhold
FRANKLIN STRATEGIC SERIES967,9820 00For
Charles Schwab599,0270 00For
JPMorgan305,4600 00For
Direxion Shares ETF Trust00 0213,276Withhold
Invesco203,6630 00For
Equitable107,9660 083,100Mixed
TIAA175,6900 00For
Russell Investments150,4830 00For
QUANTITATIVE MASTER SERIES LLC131,5280 00For
Lincoln Financial82,6630 038,615Mixed
American Century00 0109,809Withhold
Goldman Sachs00 091,413Withhold
Exchange Place Advisors Trust84,6200 00For
Northern Trust73,5400 00For
ProShares00 064,795Withhold
Voya56,0770 00For
ALPS ETF Trust00 053,700Withhold
AIG/SunAmerica00 045,624Withhold
Global X32,1160 00For
Harbor ETF Trust30,2110 00For

Showing the 25 largest of 58 asset managers. All 58 are in the interactive database (link above).

Elect Director: Troy E. Wilson, Ph.D., J.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%
FOR: 59,332,182WITHHELD: 7,740,382
Details: description as filed, official tally, votes by 58 asset managers

Description as filed by funds: Election of two Class I directors for three-year terms: Troy E. Wilson, Ph.D, J.D.

KURA ONCOLOGY INC.’s own tally for this item (“Elect Director: Troy E. Wilson, Ph.D., J.D.”): 59,332,182 for, 7,740,382 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 58 asset managers below reported 14,657,815 for, 1,810,549 withheld.

FOR
FOR: 14,657,815WITHHOLD: 1,810,549
Largest asset managers voting on “Election of two Class I directors for three-year terms: Troy E. Wilson, Ph.D, J.D.” at KURA ONCOLOGY INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard3,968,5620 00For
BlackRock3,144,0960 00For
State Street2,554,0880 037,562For
Fidelity1,706,6930 00For
Dimensional00 0996,915Withhold
FRANKLIN STRATEGIC SERIES967,9820 00For
Charles Schwab599,0270 00For
JPMorgan305,4600 00For
Direxion Shares ETF Trust00 0213,276Withhold
Invesco203,6630 00For
Equitable191,0660 00For
TIAA175,6900 00For
Russell Investments150,4830 00For
QUANTITATIVE MASTER SERIES LLC131,5280 00For
Lincoln Financial82,6630 038,615Mixed
American Century00 0109,809Withhold
Goldman Sachs91,4130 00For
Exchange Place Advisors Trust84,6200 00For
Northern Trust73,5400 00For
ProShares00 064,795Withhold
Voya00 056,077Withhold
ALPS ETF Trust00 053,700Withhold
AIG/SunAmerica00 045,624Withhold
Global X32,1160 00For
Harbor ETF Trust30,2110 00For

Showing the 25 largest of 58 asset managers. All 58 are in the interactive database (link above).

Approval of our Amended 2014 Plan

Official resultCOMPENSATIONReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

82% Approved · of votes cast

FOR 82%AGAINST
FOR: 53,621,818AGAINST: 11,993,394
Details: description as filed, official tally, votes by 60 asset managers

Description as filed by funds: APPROVAL OF AN AMENDMENT TO OUR AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN.

KURA ONCOLOGY INC.’s own tally for this item (“4. Approval of our Amended 2014 Plan”): 53,621,818 for, 11,993,394 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(4) approved our Amended 2014 Plan as disclosed in the proxy statement”
Support: 82% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of KURA ONCOLOGY INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Stock Compensation Plan” (2 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

The 60 asset managers below reported 11,960,362 for, 4,555,563 against.

FORAGAINST
FOR: 11,960,362AGAINST: 4,555,563
Largest asset managers voting on “APPROVAL OF AN AMENDMENT TO OUR AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN.” at KURA ONCOLOGY INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard3,968,5620 00For
BlackRock3,144,0960 00For
State Street27,9222,563,728 00Against
Fidelity1,641,77964,914 00For
Dimensional0996,915 00Against
FRANKLIN STRATEGIC SERIES967,9820 00For
Charles Schwab599,0270 00For
JPMorgan305,4600 00For
Direxion Shares ETF Trust0213,276 00Against
Invesco203,6630 00For
Equitable191,0660 00For
TIAA175,6900 00For
Russell Investments150,4830 00For
QUANTITATIVE MASTER SERIES LLC131,5280 00For
Lincoln Financial25,56495,714 00Mixed
American Century0109,809 00Against
Goldman Sachs091,413 00Against
Exchange Place Advisors Trust84,6200 00For
Northern Trust73,5400 00For
ProShares064,795 00Against
Voya056,077 00Against
ALPS ETF Trust053,700 00Against
ALGERT GLOBAL LLC47,5610 00For
AIG/SunAmerica045,624 00Against
Global X32,1160 00For

Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).

Advisory Vote on Executive Compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 9 wordings of this item as funds reported it.

92% Approved · of votes cast

FOR 92%
FOR: 61,538,693AGAINST: 5,449,767

Prior year: 98.3% for (May 31, 2023 meeting) ▼ 6.5 pts

Details: description as filed, official tally, votes by 183 asset managers

Description as filed by funds: APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS DURING THE YEAR ENDED DECEMBER 31, 2023.

KURA ONCOLOGY INC.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 61,538,693 for, 5,449,767 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(3) approved, on an advisory basis, the compensation paid to our named executive officers as disclosed in the proxy statement”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 59 asset managers voting on “APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS DURING THE YEAR ENDED DECE” at KURA ONCOLOGY INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard3,968,5620 00For
BlackRock3,144,0960 00For
State Street2,591,6500 00For
Fidelity1,706,6930 00For
Dimensional0996,915 00Against
FRANKLIN STRATEGIC SERIES0967,982 00Against
Charles Schwab0599,027 00Against
JPMorgan305,4600 00For
Direxion Shares ETF Trust213,2760 00For
Invesco203,6630 00For
Equitable191,0660 00For
TIAA175,6900 00For
Russell Investments0150,483 00Against
QUANTITATIVE MASTER SERIES LLC131,5280 00For
Lincoln Financial113,5927,686 00Mixed
American Century109,8090 00For
Goldman Sachs91,4130 00For
Exchange Place Advisors Trust084,620 00Against
Simplify Exchange Traded Funds00 080,000Withhold
Northern Trust73,5400 00For
ProShares64,7950 00For
Voya56,0770 00For
ALPS ETF Trust53,7000 00For
AIG/SunAmerica45,6240 00For
Global X032,116 00Against

Fund voting reports, all 59 managers: 13,539,462 for, 2,928,902 against, 80,000 withheld. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 144 asset managers voting on “APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS DURING THE YEAR ENDED DECE” at KURA ONCOLOGY INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
New York Life19,000,0000 00For
EcoR1 Capital, LLC5,806,8710 00For
SUVRETTA CAPITAL MANAGEMENT, LLC5,570,7660 00For
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)5,411,5710 00For
BVF INC/IL4,876,2930 00For
State Street3,985,2030 00For
BlackRock2,739,4829,112 00For
Avoro Capital Advisors LLC2,544,7420 00For
Paradigm Biocapital Advisors LP2,398,5410 00For
Foresite Capital Management IV, LLC1,849,9470 00For
ARMISTICE CAPITAL, LLC1,738,6990 00For
GEODE CAPITAL MANAGEMENT, LLC1,705,2030 00For
FRANKLIN ADVISERS INC30,9291,510,138 00Against
COMMODORE CAPITAL LP1,525,0000 00For
TCG Crossover Management, LLC1,423,6420 00For
Candriam S.C.A.0651,398 00Against
Charles Schwab0599,027 00Against
Northern Trust580,277733 00For
DAFNA Capital Management LLC412,6630 00For
Sofinnova Investments, Inc.381,4120 00For
JPMorgan372,4860 00For
Verition Fund Management LLC348,0070 00For
Affinity Asset Advisors, LLC346,9540 00For
MELLON INVESTMENTS Corp305,3900 00For
Logos Global Management LP0300,000 00Against

No total is shown for the institutional-manager reports: their sum exceeds the total votes cast at the meeting. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the Selection of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 69,596,811AGAINST: 56,740

Prior year: 99.9% for (May 31, 2023 meeting) unchanged

Details: description as filed, official tally, votes by 58 asset managers

Description as filed by funds: RATIFICATION OF THE SELECTION OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2024.

KURA ONCOLOGY INC.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 69,596,811 for, 56,740 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(2) ratified the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 58 asset managers below reported 16,463,928 for, 4,436 against.

FOR
FOR: 16,463,928AGAINST: 4,436
Largest asset managers voting on “RATIFICATION OF THE SELECTION OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OU” at KURA ONCOLOGY INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard3,968,5620 00For
BlackRock3,144,0960 00For
State Street2,587,2144,436 00For
Fidelity1,706,6930 00For
Dimensional996,9150 00For
FRANKLIN STRATEGIC SERIES967,9820 00For
Charles Schwab599,0270 00For
JPMorgan305,4600 00For
Direxion Shares ETF Trust213,2760 00For
Invesco203,6630 00For
Equitable191,0660 00For
TIAA175,6900 00For
Russell Investments150,4830 00For
QUANTITATIVE MASTER SERIES LLC131,5280 00For
Lincoln Financial121,2780 00For
American Century109,8090 00For
Goldman Sachs91,4130 00For
Exchange Place Advisors Trust84,6200 00For
Northern Trust73,5400 00For
ProShares64,7950 00For
Voya56,0770 00For
ALPS ETF Trust53,7000 00For
AIG/SunAmerica45,6240 00For
Global X32,1160 00For
Harbor ETF Trust30,2110 00For

Showing the 25 largest of 58 asset managers. All 58 are in the interactive database (link above).

Largest KURA ONCOLOGY INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 76,181,000 shares outstanding at the time of that meeting.

Fund voting reports: top KURA ONCOLOGY INC. shareholders by shares voted on “APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS DURING THE…”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 5.21%
2BlackRock 4.13%
3State Street 3.40%
4Fidelity 2.24%
5Dimensional 1.31%
6FRANKLIN STRATEGIC SERIES 1.27%
7Charles Schwab 0.79%
8JPMorgan 0.40%
9Direxion Shares ETF Trust 0.28%
10Invesco 0.27%
Institutional-manager reports: top KURA ONCOLOGY INC. shareholders by shares voted on “APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS DURING THE…”, 2023-2024
#Asset manager % of shares outstanding
1New York Life 24.94%
2EcoR1 Capital, LLC 7.62%
3SUVRETTA CAPITAL MANAGEMENT, LLC 7.31%
4DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 7.10%
5BVF INC/IL 6.40%
6State Street 5.23%
7BlackRock 3.61%
8Avoro Capital Advisors LLC 3.34%
9Paradigm Biocapital Advisors LP 3.15%
10Foresite Capital Management IV, LLC 2.43%

Reported KURA ONCOLOGY INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

KURA ONCOLOGY INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock9,515,135 12.49%Form 13F, quarter ended March 31, 2024
EcoR1 Capital, LLC7,683,597 10.09%Proxy statement (DEF 14A), proxy filed April 12, 2024
Suvretta Capital Management, LLC7,670,468 10.07%Proxy statement (DEF 14A), proxy filed April 12, 2024
BVF Partners L.P.7,631,926 10.02%Proxy statement (DEF 14A), proxy filed April 12, 2024
S7,472,343 9.81%Schedule 13G, filed February 13, 2024
Deerfield Management Company, L.P.5,839,229 7.66%Proxy statement (DEF 14A), proxy filed April 12, 2024
Vanguard Group5,468,522 7.18%Form 13F, quarter ended March 31, 2024
State Street4,199,954 5.51%Form 13F, quarter ended March 31, 2024
Goldman Sachs2,614,726 3.43%Form 13F, quarter ended March 31, 2024
Troy E. Wilson, Ph.D., J.D.2,290,638 3.01%Proxy statement (DEF 14A), proxy filed April 12, 2024

Percentages above are of 76,181,000 shares outstanding, as reported by KURA ONCOLOGY INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At KURA ONCOLOGY INC.'s shareholder meeting held June 5, 2024, in the 2023-2024 proxy season, 183 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,100 separate fund positions. On the most widely held item on that ballot — APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS DURING THE… — KURA ONCOLOGY INC.'s filing reports the proposal as approved, with 92% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: KURA ONCOLOGY INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 7, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from KURA ONCOLOGY INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

KURA ONCOLOGY INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “KURA ONCOLOGY (KURA) 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/kura-oncology-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.